Abstract: An electroporation device for injecting a product into a ciliary muscle of an eye includes a support having a spherical support contact surface extending along a virtual sphere having a radius between 10 and 15 mm, a first electrode comprising a curved invasive electrode needle, a second electrode having an electrically conductive electrode contact surface, and an injection needle.

Abstract: An electroporation device for injecting a product into a ciliary muscle of an eye, said device comprising: a support having a support contact surface extending along a virtual sphere having a radius between 10 and 15 mm, so as to match the outside surface of the eye, a first electrode comprising an invasive electrode needle, a second electrode having an electrically conductive electrode contact surface, optionally an injection needle, wherein the support comprises an insertion guide configured to guide a sliding of said electrode needle and/or injection needle along a respective insertion axis, so that the angle between said insertion axis and a plane tangential to the virtual sphere at the insertion point is less than 40°, the insertion point being the point where said insertion axis crosses said virtual sphere.

Abstract: An electroporation device for injecting a product into a ciliary muscle of an eye, said device comprising: a support having a support contact surface extending along a virtual sphere having a radius between 10 and 15 mm, so as to match the outside surface of the eye, a first electrode comprising an invasive electrode needle, a second electrode having an electrically conductive electrode contact surface, optionally an injection needle, wherein the support comprises an insertion guide configured to guide a sliding of said electrode needle and/or injection needle along a respective insertion axis, so that the angle between said insertion axis and a plane tangential to the virtual sphere at the insertion point is less than 40°, the insertion point being the point where said insertion axis crosses said virtual sphere.

Abstract: The present invention relates to the use of the compounds of formula (I) and their pharmaceutically acceptable salts for the treatment or the prevention of ocular inflammatory diseases, in particular for the treatment and/or prevention of uveitis, severe conjunctivitis, dry eye syndrome or diabetic retinopathy.

Abstract: Benzenesulfonamide derivative compounds corresponding to the general formula (I): and their pharmaceutically acceptable addition salts; a process for preparation of such compounds; pharmaceutical compositions containing such compounds, and the use of such compounds as a pharmacologically active substance, in particular in the treatment of neurodegenerative diseases, cardiovascular diseases, inflammatory diseases; hypercholesterolemia, and diabetes.

Abstract: Sulfonylindoline compounds of formula I, wherein R1 through R4, Y and Z have defined meanings, a process for preparation of such compounds, and the use as pharmaceutically active substances, particularly for the treatment or inhibition of neurodegeneration, cardiovascular disease, inflammatory disease, hypercholesterolemia, dyslipidemia, obesity or diabetes.

Abstract: Sulfonylindoline compounds of formula I, wherein R1 through R4, Y and Z have defined meanings, a process for preparation of such compounds, and the use as pharmaceutically active substances, particularly for the treatment or inhibition of neurodegeneration, cardiovascular disease, inflammatory disease, hypercholesterolemia, dyslipidemia, obesity or diabetes.

Abstract: Benzenesulfonamide derivative compounds corresponding to the general formula (I): and their pharmaceutically acceptable addition salts; a process for preparation of such compounds; pharmaceutical compositions containing such compounds, and the use of such compounds as a pharmacologically active substance, in particular in the treatment of neurodegenerative diseases, cardiovascular diseases, inflammatory diseases; hypercholesterolemia, and diabetes.

Abstract: The invention concerns (i) [4-(4-cyanobenzyl)phenyl]&agr;-D-glycopyranosides of formula (I) wherein: the group &agr;-D-glycopyranosyl R represents a &agr;-D-glycopyranosyl, &agr;-D-galactopyranosyl. &agr;-D-mannopyranosyl, &agr;-D-arabinopyranosyl, &agr;-D-lyxopyranosyl, or &agr;-D-ribopyranosyl group: (ii) their esters resulting from the esterification of at least a OH function of each pyranosyl group with a C2-C4 alkanoic or a cycloalkanoic acid, as novel industrial products. Said novel [4-(4-cyanobenzyl)phenyl]&agr;-D-glycopyranosides are useful in therapy for fighting against atheromatous plaque.

Abstract: The invention concerns: (i) [4-(4-cyanobenzyl)phenyl]glycopyranosides of formula (I) wherein; the glycopyranosyl group R represents a &bgr;-D arabinopyranosyl, &bgr;-D-lyxopyranosyl, &bgr;-D-ribopyranosyl, &bgr;-D-mannopyranosyl, &bgr;-L-arabinopyranosyl, &bgr;-L-xylopyranosyl, &agr;-L-arabinopyranosyl, &agr;-L-xylopyranosyl or &bgr;-L-rhamnopyranosyl group; and (ii) their esters resulting from esterification of at least a OH function of each glycopyranosyl group with a C2-C4 alkanoic or cycloalkanoic acid, as novel industrial products. Said novel [4-(4-cyanobenzyl)phenyl]glycopyranosides are useful in therapy for fighting against athermatous plaque.

Abstract: The present invention relates to compounds selected from the group consisting of:(i) the compounds of the formula ##STR1## in which: R is a hydrogen atom, a group OH, a group OCH.sub.3 or a group CH.sub.2 OH,*C, in the case where R is not a hydrogen atom, is an asymmetric carbon atom of (R,S), (R) or (S) configuration, and**C is an asymmetric carbon atom of (R,S) or (R) configuration; and(ii) their addition salts.It further relates to the method of preparing these compounds, to their use in therapeutics and in the field of analysis, and to intermediates.

Abstract: The present invention relates to a novel compound selected from the group consisting of:(i) the compounds of the formula ##STR1## in which: A is a group --CO--NH-- or a group --NH--CO--,R is a hydrogen atom or a methyl group, and*C, if R is not the hydrogen atom, is an asymmetric carbon of (R,S) or (R) configuration; and(ii) their addition salts.It further relates to the method of preparing this compound and to its use in therapeutics.

Abstract: The present invention relates, by way of novel industrial products, to compounds which are structurally related to 15-deoxyspergualin and which have the formula ##STR1## in which: A is a single bond, a group --CH.sub.2 --, a group --CH.sub.2 O--, a group --CH.sub.2 NH--, a group --CH(OH)--, a group --CHF-- or a group --CH(OCH.sub.3)--, andn is equal to 6 or 8,and their addition salts.These novel compounds are useful especially as immunosuppressants. The invention further relates to the method of preparing said compounds.

Abstract: The present invention relates, by way of novel industrial products, to compounds which are structurally related to 15-deoxyspergualin. These novel compounds have the formula ##STR1## in which: n is equal to 6 or 8 andA is a single bond, CH.sub.2, CHF, CH(OH), CH(OCH.sub.3), CH.sub.2 NH or CH.sub.2 O,and their addition salts.

Abstract: Compounds for therapeutic use of formula: ##STR1## where the chain--W--V--N--represents--N.dbd.N--N--, --N--N.dbd.N--,--O--CO--N--,--O--CS--N--, --S--CO--N--or--S--CS--N--; Ar is an aryl group; and A is a vinyl group or an alkylene chain terminated by CN, methoxy, ethoxy, OH, halogen or NH.sub.2 which may possibly be substituted.

Abstract: Compounds for therapeutic use of formula: ##STR1## where the chain--W--V--N--represents--N.dbd.N--N--, --N--N.dbd.N--, --O--CO--N--, --O--CS--N--, --S--CO--N-- or --S--CS--N--; Ar is an aryl group; and A is a vinyl group or an alkylene chain terminated by CN, methoxy, ethoxy, OH, halogen or NH.sub.2 which may possibly be substituted.